Vaxcyte, Inc. (PCVX) Announces Progress in its VAX-31 Infant Vaccine Study

Vaxcyte, Inc. (NASDAQ:PCVX) is one of the Oversold Growth Stocks to Buy According to Analysts. On September 3, Vaxcyte, Inc. (NASDAQ:PCVX) announced progress in its VAX-31 infant vaccine study for Phase 2. The drug has moved to the third and final dose-finding study after protocol changes that added a new optimized dose arm and removed the low-dose arm, with about 900 infants to be enrolled.

It compares VAX-31 to the current standard vaccine, Prevnar 20, and the company expects key safety, tolerability, and immune response data by mid-2027. CEO of Vaxcyte, Inc. (NASDAQ:PCVX), Grant Pickering, emphasized that the Optimized Dose could prompt stronger immune responses. VAX-31 aims to cover about 92% of invasive pneumococcal disease and 93% of acute otitis media cases in US children under five.

Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine company focused on developing innovative conjugate and protein vaccines to prevent or treat bacterial infectious diseases.

While we acknowledge the potential of PCVX to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PCVX and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.